Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of several combination regimens that include BRAF and MEK inhibitors, as well as the uptake of immune checkpoint inhibitors as single agents (e.g., Keytruda) and as part of combination regimens (e.g., Opdivo plus Yervoy). Despite the remarkable overall survival and progression-free survival data demonstrated by combination therapies, patients ultimately experience disease progression. Other key efficacy challenges include overcoming the relatively low response rates associated with immunotherapies and the relatively short duration of response associated with BRAF and MEK inhibitors, as well as optimizing the sequence of therapies in this crowded and competitive setting.

QUESTIONS ANSWERED

  • How satisfied are U.S. and European medical oncologists with the current treatment options for BRAF-mutation-positive unresectable or metastatic malignant melanoma ?
  • What treatment drivers and goals are most likely to influence the choice of therapy in this crowded patient population?
  • How do current therapies, such as BRAF/MEK combinations, perform on key treatment drivers and goals?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new BRAF-mutation-positive unresectable or metastatic malignant melanoma treatment opportunity?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. medical oncologists and 30 European medical oncologists.

Key drugs: Opdivo, Yervoy, Keytruda, Tafinlar, Mekinist, Zelboraf, Cotellic, Braftovi, Mektovi, Imlygic.


Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2020

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /...

View Details

Malignant Melanoma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer pati...

View Details

Malignant Melanoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of ma...

View Details